Shares of Ocugen (NASDAQ: OCGN) were skyrocketing 64.2% higher as of 11:35 a.m. EST on Monday. You could sell some or all of your Ocugen shares and buy long-term call options on the stock. The Motley Fool has no position in any of the stocks mentioned. The short answer is: everything. What Is the Best EV Stock to Buy Now? Theres even room for more lines. We have provided a few examples below that you can copy and paste to your site: Your image export is now complete. There's no way, however, to know what the COVID-19 vaccine market dynamics will be two years from now. When the symbol you want to add appears, add it to Watchlist by selecting it and pressing Enter/Return. Probably the most important thing to do after Ocugen's crash, though, is to identify lessons learned and apply them to future investing decisions. What should investors do now? The company's name was taken from Shakespeare, whose wise fools both instructed and amused, and could speak the truth to the king -- without getting their heads lopped off. Over the next few weeks, Ocugen is expected to meet with the FDA to discuss how to advance COVAXINs development. The company is led by CEO and Co-founder, Shankar Musunuri, and entered into the public equity market in 2019 via. The reverse merger with Histogenics was a disappointment, but the purchase price for the NeoCart intellectual property suggests that company had little chance of survival on its own. Concerns about the delta variant, the potential need for annual booster shots and the possibility of expanding the vaccines to children have investors hopeful that Covaxin will still eventually be a huge payoff for Ocugen. The potential synergies of such a union do not seem clear. Its worth emphasizing: Ocugen stock is a play with enormous risk. The stock dropped as low as 26 cents during the height of the pandemic fears in March 2020. Typically, I care little about financials with biotechs. Shares fell 72% on the news, and kept falling after Histogenics decided to suspend development of the product in December 2018. If you missed that action, you missed all the gains. A $30 million market capitalization doesnt mean Ocugen has no chance. Maybe it pans out for Ocugen and I wish the team (and its investors) the best of luck. The Motley Fool->. And a partnership with Chinas CanSino Biologics (OTCMKTS:CASBF) should help the company develop its pipeline. Weitere Informationen ber die Verwendung Ihrer personenbezogenen Daten finden Sie in unserer Datenschutzerklrung und unserer Cookie-Richtlinie. To be sure, current cash isnt enough. Other than an emphasis on cell therapies, the companies had almost nothing in common. Outsmart the market with Smart Portfolio analytical tools powered by TipRanks. Some of the names will rally big, putting together epic squeezes that can double or triple the stock prices in just a few days. market." When the symbol you want to add appears, add it to My Quotes by selecting it and pressing Enter/Return. From a broader perspective, the risk is the same as it is across biotech: most candidates fail. But there is no question some big-name stocks performed better than others along the way. *Stock Advisor returns as of June 7, 2021. Our 3 Top Picks. The generic form of brimonidine, the active ingredient, is not approved for the condition, according to Ocugens most recent presentation. Investors who have owned stocks in the last year have generally experienced some big gains. Thats why we give you a wide range of Options on stocks, indices, commodities and FX. Copyright With this, the newly formed Ocugen initiated a 60:1 reverse stock split. Matt McCall and the InvestorPlace Research Staff, statistics support having long-term exposure, Click here to see what Matt has up his sleeve now, There Are So Many Stocks to Buy Ocugen Isnt One of Them. The biotech stock promptly crashed by more than 30%. When the symbol you want to add appears, add it to My Quotes by selecting it and pressing Enter/Return. Unfortunately, when the market bounced in late March 2020, Ocugen kept heading lower. Learn More. Do not expect this to become the biotech who made good like Biogen (NASDAQ:BIIB). Axsome Therapeutics (NASDAQ:AXSM) had an equity value below $75 million in March 2017; its now worth over $3 billion after rising over 1,000% last year. It means that institutional investors focused on the sector largely have passed on the pipeline. The Motley Fool recommends Moderna Inc. In the late summer of 2018, the stock crashed below $1 per share as investors sold off following a failed phase three trial. Still, Ocugen investors who bought one year ago and held on have generated a huge return on their. Keith Speights for For priority reviews, the timeline for an approval decision is reduced to six months. Financial Market Data powered by FinancialContent Services, Inc. All rights reserved. Maybe. The firm's modifier gene therapy platform is engaged in addressing retinal diseases, including retinitis pigmentosa, leber congenital amaurosis, and dry age-related macular degeneration. Admittedly one could argue that it could have been bought for a quarter and sold for 75 cents, but hindsight is 20/20 in all of these names. Covaxin doesn't have an advantage in terms of dosing compared to these leading vaccines. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*. For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide. Why Ocugen Stock Is Crashing Today By Keith Speights - Mar 4, 2022 at 11:42AM Key Points The FDA gave a thumbs-down to Ocugen's EUA request for the pediatric use of Covaxin. If it goes down, your loss won't be as great as it would be if you held onto all of your shares. How can we possibly evaluate a stock on a fundamental basis with that being reality? Reaching millions of people each month through its website, books, newspaper column, radio show, television appearances, and subscription newsletter services, The Motley Fool champions shareholder values and advocates tirelessly for the individual investor. I am all for a good opportunity, but I dont know why some investors insist on penny stocks. Copyright 2023 InvestorPlace Media, LLC. Ocugen executives even sounded cautiously optimistic in the company's fourth-quarter conference call last month. The all-time high Ocugen stock closing price was, The average Ocugen stock price for the last 52 weeks is. Generally, financial analysts struggle with this sector because these equities rise and fall not on revenue or earnings, but the success of clinical trials. The sale of NeoCart, which still is pending, can bring in another $8 million, based on the current agreement. The stock ultimately hit its 2020 low on June 1 at a price of just 17 cents. 7 Penny Stocks Poised for Explosive Growth in 2023, With No Revenue or Approved Treatments, Ocugen Stock Is a Clear Sell. When the symbol you want to add appears, add it to Watchlist by selecting it and pressing Enter/Return. For now, the biggest near-term hope for Covaxin may be that Canada or another developed economy will buy the vaccine to share with developing nations. Literally, zero. 7 Penny Stocks Poised for Explosive Growth in 2023, Ocugen Stock Is Not for the Faint of Heart. An unprofitable biotech that focused on commercializing therapies to cure blindness prior to the present pandemic, Ocugen ( OCGN) stock took on a new life on December 22, when it announced. Cost basis and return based on previous market day close. With $3.2 million in cash vs. current liabilities of $3.3 million, Ocugen likely has enough cash on hand to cover its short-term obligations. Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community. CanSinoBio will be able to fund much of the development of OCU300, Ocugens flagship product that targets oGVHD (ocular graft versus host disease), a common complication of bone marrow transplants. These symbols will be available throughout the site during your session. Without NeoCart, that burn likely comes down. The FDA's decision not to issue EUA really wasn't all that surprising, though. The Motley Fool has a disclosure policy. But the allure of the space is that when a company wins, its shareholders win big. Investors need to understand the risk profile here. In December, Ocugen stated that it had put together an advisory board of "leading academic and industry experts to evaluate the clinical and regulatory path to approval in the U.S. The statistics support having long-term exposure to this asset class. (To watch Ramakanths track record, click here), In contrast, all 3 other analysts who have recently posted an Ocugen review rate the stock a Buy. Histogenics itself highlights the risks involved in small-cap biotech. For now, though, what happens in India stays in India. The Motley Fool has a disclosure policy. Sie knnen Ihre Einstellungen jederzeit ndern, indem Sie auf unseren Websites und Apps auf den Link Datenschutz-Dashboard klicken. The company's product pipeline consists of OCU400, OCU300, OCU100 and OCU200 which are in clinical stage. Please check your download folder. The company initiated its Phase 3 trial of OCU300 back in July 2018. Klicken Sie auf Alle ablehnen, wenn Sie nicht mchten, dass wir und unsere Partner Cookies und personenbezogene Daten fr diese zustzlichen Zwecke verwenden. Shares of Ocugen (OCGN 4.03%) were crashing 19.2% lower as of 11:23 a.m. Hence, instead of ruining just two lives, this new Ocugen may be destroying the investment future of all who buy. Lorem ipsum dolor sit amet, consectetur adipiscing elit. So far, that merger hasnt worked out for Histogenics former shareholders. Not an offer or recommendation by Stocktwits. Thats one of the best rallies weve seen in that amount of time (95 trading sessions, 136 days). Ocugen isnt a promotional, fly-by-night penny stock. And its at least possible that OCGN could wind up being a winner. Shares of Ocugen (OCGN) skyrocketed over 800% in the past three trading sessions after the biopharmaceutical company disclosed it had signed a binding letter of intent (LOI) with India based Bharat Biotech to co-develop a COVID-19 vaccine for the U.S. market. The stock had gained some traction after they announced the. The Nasdaq has been even more impressive, rallying 67.7% in the same time frame and hitting new all-time highs in the process. Instead of buying a piece of the S&P 500 or Nasdaq or even better, a common sense mega-holding like Apple (NASDAQ:AAPL) or Amazon investors in OCGN stock took on a high-risk investment and for months saw negative returns. What Is the Best EV Stock to Buy Now? I will just say this on Ocugen: Theres a reason it trades for sub-$1 after hitting resistance near $180 in 2018. Some were undoubtedly anticipating a relatively quick EUA win for Covaxin followed by strong U.S. sales for the COVID-19 vaccine. But if they do, Ocugen stock at the least looks like an intriguing bet. Still, Ocugen investors who bought one year ago and held on have generated a huge return on their investment. The reverse merger that brought Ocugen to the public markets led to huge losses but some investors are buying the dip. The Ocugen 52-week low stock price is 0.93, which is 1.1% below the current share price. Objective investors could have clearly seen then that there actually were significant reasons to be concerned. As of this writing, Matt did not hold a position in any of theaforementioned securities. In 2018, its NeoCart biologic failed to meet the primary endpoint of its own Phase III trial. OCGN Ocugen Inc 155,223 $0.9721 $0.0263 (2.63%) If you already owned Ocugen stock before the company's disappointing news, you have several alternatives. But any success they find will be without me as a shareholder. Its top officers have experience at Pfizer (NYSE:PFE) and other well-respected pharmaceutical and biotechnology companies. Biotechnology stocks like Ocugen (NASDAQ:OCGN) are among the markets riskiest plays. The first is that Ocugen is facing potential delisting from the NASDAQ given that its share price still sits well below $1. Emergency Use Authorization (EUA) for Covaxin, the COVID-19 vaccine developed by Ocugen's partner, Bharat Biotech. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. 2023, Nasdaq, Inc. All Rights Reserved. The company has a gene therapy platform as well as two preclinical compounds that aim to treat retinal diseases. 1125 N. Charles St, Baltimore, MD 21201. ET on Friday. In fact, $1,000 in Ocugen stock bought on Aug. 9, 2020, would be worth about $15,100 today. Maybe OCGN stock will be one of them again. Keith Speights for Now, with the stock trading near the 40-cent per share level, its prospects have taken a dramatic turn for the worse. Shares of Ocugen ( OCGN) skyrocketed over 800% in the past three trading sessions after the biopharmaceutical company disclosed it had signed a binding letter of intent (LOI) with India based. Still, Ocugens balance sheet isnt as dire as its share price might suggest. Assuming it wins approval for the vaccine, the challenge for the company then will be to achieve commercial success. Shares fell 72% on the news, and kept falling after Histogenics decided to suspend development of the product in December 2018. InvestorPlace - Stock Market News, Stock Advice & Trading Tips. After encouraging preliminary results, Ocugen began trying to sell 100 million doses of the vaccine in February. The market capitalization of Relmada Therapeutics (NASDAQ:RLMD) went from under $10 million at the end of 2017 to over $500 million at the moment.
